PharmaCyte Biotech Inc (PMCB)

[Triple9]

Patterns patterns everywhere...

$PMCB files $50 MIllion Shelf registration:

http://ir.pharmacytebiotech.com/all-sec-filings/content/0001683168-17-002356/pharmacyte_s3-091117.htm#a11

Janssen is paying Protagonist $50 million up front, with a commitment for up to $940 million more tied to development, regulatory, and sales milestones. Janssen, a subsidiary of New Brunswick, NJ-based Johnson & Johnson (NYSE: JNJ), would receive worldwide rights to the drug and Protagonist would get royalties on sales of a commercialized product.

http://www.xconomy.com/san-francisco/2017/05/30/protagonist-janssen-ink-development-deal-for-crohns-disease-drug/#

Separately, Johnson & Johnson Innovation — JJDC, Inc. is making a $50 million equity investment in TESARO

http://ir.tesarobio.com/releasedetail.cfm?releaseid=963728